Develops intranasal drug candidates for patients with social anxiety, depression, and menopausal hot flashes.
10-K for FY2026, filed Jun 15, 2026
The company earns sublicense and other revenue under agreements with AffaMed and Fuji Pharma. It can earn an upfront license fee when a partner can use licensed intellectual property, or earn revenue over time when a license is bundled with research services.
10-K for FY2026, filed Jun 15, 2026
$1.3M
10-K for FY2026, filed Jun 15, 2026
$1.3M ↗
AffaMed and Fuji Pharma are parties to agreements that generate sublicense and other revenue.
10-K for FY2026, filed Jun 15, 2026Sublicense and other revenue consist of revenue recognized under the AffaMed Agreement and Negotiation Agreement with Fuji Pharma. Revenue…View ↗
No. It lost $69.7M in FY2026.
Growing. Revenue grew 14% in 4 years, from $1.1M in FY2022 to $1.3M in FY2026, about 3% a year.
Expanded women's health use
The older report lists menopausal hot flashes and migraine for a pherine candidate; the latest also describes refisolone for premenstrual dysphoric disorder.
10-K for FY2023, filed Jun 28, 2023 10-K for FY2026, filed Jun 15, 2026Five of our product candidates – fasedienol (PH94B), itruvone (PH10), PH15, PH80 and PH284 – belong to a new class of synthetic neuroactive…View ↗
Competes with Vanda Pharmaceuticals, Tonix Pharmaceuticals, Sensorium Therapeutics, Engrail Therapeutics, Axsome Therapeutics, Definium Therapeutics, Xenon Pharmaceuticals, Johnson & Johnson, Usona Institute, Neumora Therapeutics, Boehringer Ingelheim, Syndeio Biosciences, Suven Life Sciences, GH Research, Draig Therapeutics, HMNC Brain Health, Sirtsei Pharmaceuticals, Astellas Pharma, Bayer, and Gedeon Richter
10-K for FY2026, filed Jun 15, 2026Currently there is no FDA-approved acute treatment of SAD, and we are aware of no company developing a potential acute treatment of SAD…View ↗
Loading...